Search

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Treatment, medicine and hematology research: What patients want and doctors need (to know)

Jan Geissler, a Patient Advocate remarked about the Congress: “Over and above scientific updates, much can be achieved in partnership between hematologists and patients.

Read more

Regulatory affairs & scientific relations

EHA’s regulatory work: European Medicines AgencyMost of EHA’s regulatory work entails collaboration with the European Medicines Agency (EMA).

Read more

Clinical Practice Guidelines

EHA creates clinical practice Guidelines for diagnosis and treatment of hematologic diseases. This initiative started in 2019 with the establishment of the EHA Guidelines Committee and the definition of the EHA Methodology for Guidelines.

Read more

EHA Diversity, Equity, and Inclusion Award 2024

The EHA Diversity, Equity, and Inclusion (DEI) Award celebrates achievements that foster inclusivity. It recognizes efforts taken by individuals, teams, or organizations (collectively “candidate”) to promote DEI within leadership, initiatives, and overall work.

Read more

SWG Educational Activities

EventsSWG AML Annual Scientific MeetingThe most recent SWG AML Annual Scientific Meeting took place during the annual EHA Congress in Frankfurt, Germany.

Read more

European Affairs

Advocating & collaborating for hematologyEHA serves as the face and voice of hematology and hematology professionals in Europe.

Read more

Turkey tutorial focused on lymphoma

The 8th EHA-TSH Hematology Tutorial was held on April 6-7, 2019 in Izmir, Turkey. This marks yet another pleasant and fruitful collaboration between EHA and the Turkish Society of Hematology.

Read more